Literature DB >> 21918492

Influenza-associated pediatric deaths--United States, September 2010-August 2011.

.   

Abstract

Influenza-associated pediatric mortality has been a nationally notifiable condition since October 2004. This report summarizes the 115 cases of influenza-associated pediatric mortality reported to CDC that occurred from September 1, 2010, through August 31, 2011. Deaths occurred in 33 states. Nearly half of the deaths (46%) occurred in children aged <5 years. Of the children who died, 49% had no known Advisory Committee on Immunization Practices (ACIP)-defined high-risk medical conditions, and 35% died at home or in the emergency department. Of the 74 children aged ≥6 months for whom vaccination data were available, 17 (23%) had been fully vaccinated. ACIP recommends that all children aged ≥6 months receive vaccination against influenza annually. These findings underscore the importance of vaccinating children to prevent influenza virus infection and its potentially severe complications. Health-care providers should develop a comprehensive strategy to increase vaccination coverage among children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21918492

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  30 in total

1.  Case fatality and population mortality associated with anaphylaxis in the United States.

Authors:  Larry Ma; Theodore M Danoff; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-12-14       Impact factor: 10.793

2.  Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.

Authors:  Guha Asthagiri Arunkumar; Andriani Ioannou; Teddy John Wohlbold; Philip Meade; Sadaf Aslam; Fatima Amanat; Juan Ayllon; Adolfo García-Sastre; Florian Krammer
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  Automated Screening of Hospitalized Children for Influenza Vaccination.

Authors:  Ari H Pollack; Matthew P Kronman; Chuan Zhou; Danielle M Zerr
Journal:  J Pediatric Infect Dis Soc       Date:  2013-08-06       Impact factor: 3.164

4.  The use of antiviral drugs for influenza: Guidance for practitioners, 2012/2013; Paediatric summary.

Authors:  Upton D Allen
Journal:  Paediatr Child Health       Date:  2013-03       Impact factor: 2.253

5.  The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism.

Authors:  Yong Liu; Yongfeng Yang; Jialin Fan; Ruina He; Ming Luo; Xiaofeng Zheng
Journal:  J Biol Chem       Date:  2015-02-17       Impact factor: 5.157

6.  Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program-Results from a randomized controlled trial.

Authors:  Byung-Kwang Yoo; Sharon G Humiston; Peter G Szilagyi; Stanley J Schaffer; Christine Long; Maureen Kolasa
Journal:  BMC Health Serv Res       Date:  2015-11-16       Impact factor: 2.655

7.  The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013.

Authors:  Fred Y Aoki; Upton D Allen; H Grant Stiver; Gerald A Evans
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

8.  Sustainability of school-located influenza vaccination programs in Florida.

Authors:  Cuc H Tran; Joe Brew; Nicholas Johnson; Kathleen A Ryan; Brittany Martin; Catherine Cornett; Brad Caron; R Paul Duncan; Parker A Small; Paul D Myers; J Glenn Morris
Journal:  Vaccine       Date:  2016-04-25       Impact factor: 3.641

9.  Influenza-associated pediatric deaths in the United States, 2004-2012.

Authors:  Karen K Wong; Seema Jain; Lenee Blanton; Rosaline Dhara; Lynnette Brammer; Alicia M Fry; Lyn Finelli
Journal:  Pediatrics       Date:  2013-10-28       Impact factor: 7.124

10.  The coming era of quadrivalent human influenza vaccines: who will benefit?

Authors:  Ian G Barr; Lauren L Jelley
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.